Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference
Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference
ST. LOUIS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 36th Annual Healthcare Conference.
美国圣路易斯,2024年11月26日 (GLOBE NEWSWIRE) -- stereotaxis(纽交所代码:STXS),作为微创血管介入手术机器人领域的先驱和全球领导者,今天宣布董事长兼首席执行官大卫·费歇尔将参与派杰投资第36届年度医疗会议。
Mr. Fischel will deliver a formal presentation on Stereotaxis' technology and growth strategy on Thursday, December 5, 2024, at 2:00 pm ET. Mr. Fischel will be available for one-on-one meetings that same day.
费歇尔先生将于2024年12月5日星期四下午2:00(东部时间)对stereotaxis的科技和增长策略进行正式演讲。费歇尔先生当天将提供一对一的会议。
"This is an exciting period for Stereotaxis and we look forward to sharing our progress in realizing an attractive growth strategy," said Mr. Fischel. "We appreciate the opportunity to engage with investors at the Piper Sandler conference."
费歇尔先生表示:“这是stereotaxis一个令人兴奋的时期,我们期待分享在实现有吸引力的增长策略方面的进展。我们感谢在派杰投资会议上与投资者交流的机会。”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit .
关于Stereotaxis
Stereotaxis(纽交所:STXS)是微创血管介入创新手术机器人领域的先驱和全球领导者。其使命是发现、开发和提供用于介入实验室的机器人系统、仪器和信息解决方案。这些创新帮助医生以机器人精确度和安全性提供无与伦比的患者护理,扩大微创治疗的可及性,并提高手术室中的生产力、连接性和智能性。Stereotaxis技术已在美国、欧洲、亚洲及其他地区用于治疗超过150,000名患者。有关更多信息,请访问 .
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
本新闻稿包含可能构成“前瞻性”声明的陈述,通常包含“相信”,“估计”,“预测”,“预期”或类似表述的词语。前瞻性声明固有地涉及风险和不确定性,可能导致实际结果与其显著不同。导致或有助于此类差异的因素包括但不限于公司能否将费用管理在可持续水平上,市场对公司产品的接受程度,全球经济状况对客户购买其技术的能力和意愿的影响,竞争因素,与医疗保健政策相关的变化,对第三方厂商的依赖,监管批准的时间,大流行病或其他灾难的影响,以及与我们最近收购APt相关的陈述,包括从收购中预期的任何好处,以及公司在其采购订单和其他承诺方面的营收确认的无保证,因为其中一些采购订单和其他承诺受到公司无法控制的不确定因素的影响,可能会被修订、修改、延迟或取消。通过发表这些前瞻性声明,公司不承担更新这些声明的责任,也不承诺在本新闻稿发布日期之后对这些声明进行修订或更改。
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
立体定向联系方式:
David L. Fischel
董事长兼首席执行官
Kimberly Peery
Chief Financial Officer
Kimberly Peery
首席财务官
314-678-6100
Investors@Stereotaxis.com
314-678-6100
Investors@Stereotaxis.com